NAFDAC targets WHO maturity level four for local vaccines highest level

The National Agency for Food and Drug Administration and Control (NAFDAC) is working towards attaining the World Health Organisation (WHO) Maturity level four (ML4) status for local vaccine manufacturing between this year and 2028.

The Director General of NAFDAC, Prof. Mojisola Adeyeye, stated this yesterday while briefing newsmen in Abuja.

Maturity level four (ML4) is the highest level in WHO’s classification of regulatory authorities for medical products.

Adeyeye, who was recently reappointed by President Muhammadu Buhari for a second term, said attaining WHO ML4 and World Listed Authority (WLA) status would enable global trade of Nigerian-made pharmaceuticals through collaborative registration with other regulatory agencies.

EFCC secures 3, 785 convictions in 2022

COVID-19 variants surging in other countries not in Nigeria – NCDC

She said it would also ensure good manufacturing practices of Nigeria Vaccine Company, and assure quality, safety and efficacy of vaccines manufactured in Nigeria or export.

Adeyeye said the agency also targeted increasing internally generated revenue (IGR) and user fees by 20 per cent from the current levels based on the availability of more infrastructure and tools.

While saying the agency would create a women’s health office, she added that it would ensure continual vigilance to reduce substandard, falsified and counterfeit medicines and narcotics.